Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Market Cap	131.15B
Revenue (ttm)	13.05B
Net Income (ttm)	4.65B
Shares Out	5.93B
EPS (ttm)	0.78
PE Ratio	28.26
Forward PE	27.64
Dividend	0.34 (1.52%)
Ex-Dividend Date	Jul 3, 2025

Volume	5,558,080
Average Volume	15,026,514
Open	21.95
Previous Close	21.85
Day's Range	21.75 - 22.20
52-Week Range	14.96 - 25.90
Beta	0.71
RSI	54.12
Earnings Date	Mar 27, 2025

About HKG:3692

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3692

Financial Performance

In 2024, HKG:3692's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY